BioXcel Therapeutics (BTAI) Stock Price, Quote, News & History | Benzinga

BioXcel Therapeutics (BTAI) Stock Price, Quote, News & History

BTAINASDAQ

Logo brought to you by Benzinga Data

Trade with Public

Trade with Public

$1.58

-0.01-0.63%

At close: Feb 2, 4:00 PM EST

$1.58

N/A

After Hours: 6:23 PM EST

Overview

News Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$1.60

Close

$1.58

Volume / Avg.

477.40K / 603.06K

Day Range

$1.54 - $1.63

52 Wk Range

1.17 - 8.08

Market Cap

$34.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

34

Short Interest

4.84%

Days to Cover

2.24

Recent BioXcel Therapeutics Inc News

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

BioXcel's Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its at-home treatment use.

Vandana Singh

EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Chris Katje

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

BioXcel's Phase 3 trial shows BXCL501 safely reduces agitation in schizophrenia patients, supporting plans for an FDA label expansion.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-58.21M

Investing Cash Flow (TTM)

0

Financing Cash Flow (TTM)

55.15M

Free Cash Flow (TTM)

-58.21M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-3.07M

Analyst Trends and Forecast

3

Aug 25

1

1

Sep 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.1

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$107.66M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

15.87

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-584.28%

Earnings Yield % (FWD)

-112.89%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$4.07

Company Debt

Total Debt

$109.13M

LT Debt

$92.30M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$36.18M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.60

Close

$1.58

Volume / Avg.

477.40K / 603.06K

Day Range

$1.54 - $1.63

52 Wk Range

1.17 - 8.08

Market Cap

$34.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

34

Short Interest

4.84%

Days to Cover

2.24

About

Sector

Health Care

Industry

Biotechnology

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeli...

Show More

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy BioXcel Therapeutics (BTAI) stock?

A

You can purchase shares of BioXcel Therapeutics (NASDAQ:BTAI) through any online brokerage.

View our list of the best stock brokerages

Q

Who are BioXcel Therapeutics (BTAI) competitors?

A

Other companies in BioXcel Therapeutics’s space includes: Serina Therapeutics Inc (AMEX:SER), Outlook Therapeutics Inc (NASDAQ:OTLK), Kyntra Bio Inc (NASDAQ:KYNB), Skye Bioscience Inc (NASDAQ:SKYE) and Cue Biopharma Inc (NASDAQ:CUE).

Q

What is the forecast, or price target, for BioXcel Therapeutics (BTAI) stock?

A

BioXcel Therapeutics has a consensus price target of $19.69.

Q

What is the current price for BioXcel Therapeutics (BTAI)?

A

The stock price for BioXcel Therapeutics (NASDAQ: BTAI) is $1.58 last updated February 2, 2026 at 6:23 PM EST.

Q

Does BioXcel Therapeutics (BTAI) pay a dividend?

A

There are no upcoming dividends for BioXcel Therapeutics.

Q

When is BioXcel Therapeutics (NASDAQ:BTAI) reporting earnings?

A

BioXcel Therapeutics does not have any upcoming earnings scheduled.

Q

Is BioXcel Therapeutics (BTAI) going to split?

A

There is no upcoming split for BioXcel Therapeutics.

Q

What sector and industry does BioXcel Therapeutics (BTAI) operate in?

A

BioXcel Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Serina Therapeutics Inc

Outlook Therapeutics Inc

Skye Bioscience Inc

Cue Biopharma Inc

Xilio Therapeutics Inc

OnKure Therapeutics Inc

Dyadic International Inc